QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module VIII PASS Results, Reporting and Regulatory Follow-up

Test your understanding of the concepts covered by GVP Module VIII: PASS Results, Reporting and Regulatory Follow-up.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which feature most strongly demonstrates that a final PASS report is scientifically traceable?

A large number of tables and figures A conclusion linked through the population, dataset, analysis, results and limitations to the protocol objective A conclusion written by an external statistician A report that excludes protocol deviations to avoid confusing the reader

Question 2 of 10 A primary-data-collection PASS identifies individual suspected adverse reactions. Which statement best reflects the required interface with pharmacovigilance operations?

The cases remain exclusively in the research database until study closure. The cases are subject to applicable adverse-reaction requirements and should be recorded and summarised in interim and final study reporting. The cases are excluded because PASS data cannot be used for individual case processing. Only events judged unrelated to the medicine require processing.

Question 3 of 10 A delay affects the planned completion date of a PASS that is subject to a regulatory obligation. What should the organisation assess?

Only whether the vendor can maintain its revised internal schedule Whether the delay affects regulatory milestones, safety-information timing, marketing-authorisation conditions or the ability to answer the safety question Only whether the final report can still be formatted on time Whether the study can be reclassified as voluntary without regulatory interaction

Question 4 of 10 For an imposed non-interventional PASS, which milestone is most directly relevant to determining whether the final analytical dataset is available?

The date on which the study team holds its close-out meeting The date on which all vendor invoices are paid The availability of the dataset needed for analyses leading to the primary study results The date on which the database was first opened

Question 5 of 10 A regulatory commitment is linked to an imposed PASS. Which event alone is insufficient to demonstrate closure of the commitment?

Documented completion of required implementation activities Resolution of outstanding authority questions Locking the study database and approving the final report Verification that downstream obligations have been addressed

Question 6 of 10 Which sequence best represents a defensible interpretation of PASS results?

Statistical significance, regulatory action, protocol review, uncertainty assessment Protocol objective, evidence actually generated, remaining uncertainty, justified conclusion Conclusion, data collection, protocol deviation assessment, primary objective Regulatory outcome, MAH opinion, study conduct, analytical dataset

Question 7 of 10 What is the principal regulatory significance of registering an imposed non-interventional PASS in the HMA-EMA Catalogue of real-world data studies?

Registration replaces the need for a final study report. Registration supports public transparency and should remain consistent with the actual study status and formal documents. Registration converts a voluntary PASS into an imposed PASS. Registration is limited to studies that produce a regulatory variation.

Question 8 of 10 A PASS addresses an RMP risk-minimisation objective and finds that the communication reached prescribers but did not improve the predefined behaviour. What is the best interpretation?

Distribution alone proves effectiveness. The result should be assessed against the prespecified effectiveness objective and may support reassessment of the risk-minimisation strategy. The result is irrelevant because the RMP belongs to a different function. The study automatically determines the exact replacement measure.

Question 9 of 10 For an imposed non-interventional PASS, which body performs the applicable assessment of the final study report under the Article 107q procedure?

The study vendor The QPPV acting as the regulatory authority The Pharmacovigilance Risk Assessment Committee (PRAC) The marketing authorisation holder's clinical study team

Question 10 of 10 Which statement best describes the relationship between a completed PASS and a subsequent PSUR?

The PASS becomes irrelevant once its final report is submitted. Relevant PASS findings and resulting actions should inform later aggregate safety evaluation, including PSURs where applicable. The PSUR replaces the final PASS report and should contain no reference to it. Only negative PASS findings may be included in a PSUR.

QPPV.com

Knowledge Assessment: GVP Module VIII PASS Results, Reporting and Regulatory Follow-up

Cookie Settings